Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by itntdfon Jan 16, 2024 12:48pm
168 Views
Post# 35829383

RE:RE:RE:open for business

RE:RE:RE:open for businessandrew's wife has a number of companies which could be considered somewhat competitive to oncy or at least put andrew in a position of possibly violating any non-compete agreements he might have had under his contract or under his termination agreement.

since his agreement provided for termination by either party virtually immediately, unless for cause, and there is no current indication as to why he left, maybe consultancy was his best way to go.

also, under terms of his agreement, he was subject to somewhere between 3 and 6 months of pay and any accrued or owed benefits if/when either party terminated the agreement for reasons other than cause.

one leasing site said the la jolla office was immediately available while another one said available april 1.  can't find any info regarding obus leasing a new office yet or hiring a replacement for andrew.
<< Previous
Bullboard Posts
Next >>